Amorphous solid dispersions of enzalutamide and novel polysaccharide derivatives: investigation of relationships between polymer structure and performance

• Published in: Scientific reports Vol. 10; no. 1; p. 18535
• Main Authors: Wilson, Venecia R., Lou, Xiaochun, Osterling, Donald J., Stolarik, DeAnne F., Jenkins, Gary J., Nichols, Brittany L. B., Dong, Yifan, Edgar, Kevin J., Zhang, Geoff G. Z., Taylor, Lynne S.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 28.10.2020; Nature Publishing Group
• Subjects: 639/301/923/1028; 692/308/153; Absorption; Animals; Cellulose; Crystallization; Drug Delivery Systems - methods; Humanities and Social Sciences; Hydrophobic and Hydrophilic Interactions; Hydrophobicity; Male; multidisciplinary; Phenylthiohydantoin - administration & dosage; Phenylthiohydantoin - analogs & derivatives; Phenylthiohydantoin - chemistry; Phenylthiohydantoin - pharmacology; Polymers; Polymers - chemistry; Polysaccharides; Polysaccharides - chemistry; Polysaccharides - pharmacology; Prostate cancer; Rats; Rats, Sprague-Dawley; Science; Science (multidisciplinary); Solubility; Water - chemistry
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-75077-7

Amorphous solid dispersion (ASD) is a widely employed formulation technique for drugs with poor aqueous solubility. Polymers are integral components of ASDs, but mechanisms by which polymers lead to the generation and maintenance of supersaturated solutions, which enhance oral absorption in vivo, are poorly understood. Herein, a diverse group of newly synthesized cellulose derivatives was evaluated for their ability to inhibit crystallization of enzalutamide, a poorly soluble compound used to treat prostate cancer. ASDs were prepared from selected polymers, specifically a somewhat hydrophobic polymer that was extremely effective at inhibiting drug crystallization, and a less effective, but more hydrophilic, crystallization inhibitor, that might afford better release. Drug membrane transport rate was evaluated in vitro and compared to in vivo performance, following oral dosing in rats. Good correlation was noted between the in vitro diffusion cell studies and the in vivo data. The ASD formulated with the less effective crystallization inhibitor outperformed the ASD prepared with the highly effective crystallization inhibitor in terms of the amount and rate of drug absorbed in vivo. This study provides valuable insight into key factors impacting oral absorption from enabling ASD formulations, and how best to evaluate such formulations using in vitro approaches.